Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk

Recruiting now

Conditions studied: Pancreatic Cancer

In brief

The study is a prospective, observational study evaluating the utility of endoscopic ultrasound or MRI for the identification of preneoplastic and neoplastic pancreatic lesions in patients at high risk for pancreatic cancer, specifically those with BRCA1/2, ATM, or PALB2 mutations.

Key facts

Study ID

NCT02478892

Run by

Abramson Cancer Center at Penn Medicine

People needed

200

Starts

2015-05-01

Expected to finish

2030-05-01

Last updated by the study team

2026-02-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age >= 18
• Documented germline pathogenic or likely pathogenic BRCA1, BRCA2, ATM, or PALB2 mutation
• If no history of PDAC in a first or second degree relative, age >= 50
• If there is a history of PDAC in a first or second degree relative, minimum age of eligibility is 10 years younger than the age of onset of the youngest relative with pancreatic cancer

You may not qualify if…

• Pregnancy

Where it is running

• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.